Essential medicines are still essential

The Lancet

Volumn 386, Issue 10004, 2015, Pages 1601-1603

  Gray, Andy L ^a,b   Wirtz, Veronika J ^a,c   'T Hoen, Ellen F M ^e   Reich, Michael R ^a,d   Hogerzeil, Hans V ^a,e  

^a Lancet Commission on Essential Medicines Policies   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; COST; COST EFFECTIVENESS ANALYSIS; DRUG DOSAGE FORM; DRUG RESISTANT TUBERCULOSIS; ESSENTIAL MEDICINE; GOVERNMENT; HUMAN; MANAGED CARE; MEDICINE; NOTE; PRIORITY JOURNAL; QUALITY CONTROL; SUSTAINABLE DEVELOPMENT; WORLD HEALTH ORGANIZATION; CLASSIFICATION; ECONOMICS;

DRUG;

PHARMACEUTICAL PREPARATIONS; WORLD HEALTH ORGANIZATION;

EID: 84945366208     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00514-0     Document Type: Note

References (15)

1. WHO The selection and use of essential medicines. Report of the WHO Expert Committee. Technical Report Series 994 2015 World Health Organization Geneva http://apps.who.int/iris/bitstream/10665/189763/1/9789241209946-eng.pdf (accessed Oct 20, 2015).
2. WHO The 19th WHO model list of essential medicines 2015 World Health Organization Geneva http://www.who.int/medicines/publications/essentialmedicines/EML2015-8-May-15.pdf (accessed Oct 9, 2015).
3. WHO Patent situation of key products for treatment of hepatitis C: sofosbuvir 2015 World Health Organization Geneva http://www.who.int/phi/implementation/ip-trade/sofosbuvir-report-updated.pdf?ua=1 (accessed Oct 9, 2015).
4. New York Times Costly Hep C medicines for everyone? New York Times Sept 2, 2015 http://www.nytimes.com/2015/09/02/opinion/costly-hepatitis-c-drugs-for-everyone.html?emc=eta1&-r=0 (accessed Oct 9, 2015).
5. WHO The selection and use of essential medicines. Report of the WHO Expert Committee, 2002. Technical Report Series 914: 14-17 2002 World Health Organization Geneva
6. S Manikandan Are we moving towards a new definition of essential medicines? J Pharmacol Pharmacother 6 2015 123 125
7. WHO The selection and use of essential medicines. Report of the WHO Expert Committee. Technical Report Series 985 2013 World Health Organization Geneva
8. WHO Report of the WHO Expert Committee, 2005. Technical Report Series 933 2005 World Health Organization Geneva
9. H Hogerzeil The concept of essential medicines: lessons for rich countries BMJ 329 2004 1169
10. C Moucheraud, VJ Wirtz, MR Reich Evaluating the quality and use of economic data in decisions about essential medicines Bull World Health Organ 93 2015 693 699
11. N van de Ven, J Fortunak, B Simmons et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis-C virus Hepatology 61 2015 1174 1182
12. WHO Proposal for the inclusion of trastuzumab in the WHO Model List of Essential Medicines for the treatment of HER2-Positive breast cancer 2012 World Health Organization Geneva http://www.who.int/selection-medicines/committees/expert/19/applications/Trastuzumab2-8-2-A-Ad.pdf (accessed Oct 9, 2015).
13. World Trade Organization Pharmaceutical patents and the TRIPS Agreement 2006 World Trade Organization https://www.wto.org/english/tratop-e/trips-e/pharma-ato186-e.htm (accessed Oct 9, 2015).
14. WHO WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers 2015 World Health Organization Geneva http://www.who.int/mediacentre/news/releases/2015/new-essential-medicines-list/en/ (accessed Oct 9, 2015).
15. The Lancet A new Lancet Commission on essential medicines Lancet 384 2014 1642